Lipoprotein Apheresis
Patrick M Moriarty1, Linda Hemphill2
1Division of Clinical Pharmacology and Atherosclerosis/Lipoprotein-Apheresis Center, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3008, Kansas City, KS 66160, USA.
Insights
Lipoprotein apheresis (LA) therapy effectively lowers low-density lipoprotein cholesterol (LDL-C) and reduces cardiovascular events in familial hypercholesterolemia (FH) patients. This treatment also decreases Lp(a) levels, inflammatory markers, and blood viscosity.
Area of Science:
- Cardiology
- Metabolic Disorders
- Vascular Medicine
Background:
- Familial hypercholesterolemia (FH) patients experience premature atherosclerosis and cardiovascular disease (CVD).
- Standard lipid-lowering medications may not sufficiently reduce elevated low-density lipoprotein cholesterol (LDL-C) in FH patients.
- Lipoprotein apheresis (LA) is an established therapy for managing severe hypercholesterolemia.
Purpose of the Study:
- To evaluate the clinical benefits of Lipoprotein apheresis (LA) in patients with familial hypercholesterolemia (FH).
- To assess the efficacy of LA in reducing cardiovascular disease (CVD) events and specific lipid markers.
Main Methods:
- Lipoprotein apheresis (LA) therapy administered to patients with familial hypercholesterolemia (FH).
- Monitoring of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) [Lp(a)] levels before and after treatment.
- Assessment of cardiovascular disease (CVD) event rates and other biomarkers like inflammatory markers and blood viscosity.
Main Results:
- Lipoprotein apheresis (LA) achieved over 60% reduction in LDL-C levels in FH patients.
- LA therapy demonstrated a significant reduction in cardiovascular disease (CVD) events.
- LA treatment also led to decreased levels of Lp(a), inflammatory markers, and improved blood viscosity.
Conclusions:
- Lipoprotein apheresis (LA) is a clinically beneficial therapy for reducing cardiovascular events in familial hypercholesterolemia (FH) patients.
- LA effectively lowers both LDL-C and Lp(a) levels, contributing to reduced CVD risk.
- The therapy offers additional benefits by reducing inflammatory markers and blood viscosity in FH patients.
Abstract:
Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients with FH with hypercholesterolemia. LA reduces LDL-C levels by more than 60% in patients with FH and reduces CVD events. LA also reduces Lp(a) levels and CVD events. LA reduces inflammatory markers and blood viscosity.
